Evidence map›Paper›PMID 41836730›Full record

ReviewInternational journal of nanomedicine2026

Design Evolution of Curcumin-Loaded Nanostructured Lipid Carriers: Formulation Strategies, Functional Modifications, and Mechanistic-Translational Perspectives.

Ikra Nurohman, Cecep Suhandi, Anis Yohana Chaerunisaa, Gofarana Wilar, Garnadi Jafar, Sriwidodo Sriwidodo

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ikra NurohmanDoctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.
Cecep SuhandiDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.ORCID 0000-0001-7746-3271
Anis Yohana ChaerunisaaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.ORCID 0000-0002-4985-8206
Gofarana WilarDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.
Garnadi JafarDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Bhakti Kencana, Bandung, 40614, Indonesia.
Sriwidodo SriwidodoDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.ORCID 0000-0003-3049-8375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin possesses broad therapeutic potential but remains severely limited by poor solubility, instability, and low systemic bioavailability. Nanostructured lipid carriers (NLCs) have emerged as an advanced lipid-based delivery platform capable of overcoming these constraints through optimized lipid organization, high drug-loading capacity, and tunable surface functionality. This review provides a comprehensive examination of the design evolution of curcumin-loaded NLCs (Cur-NLCs), encompassing core components, formulation strategies, preparation techniques, and quality determinants that govern physicochemical and biological performance. Evidence-based classification of formulation approaches is presented, highlighting single-drug, co-loaded, and surface-modified or functionally engineered NLC systems and their respective therapeutic advantages. Mechanistic insights are discussed to elucidate how NLCs enhance curcumin's stability, absorption, intracellular trafficking, and controlled release. Current challenges, including formulation heterogeneity, scalability, long-term stability, and translational readiness, are critically evaluated, alongside emerging clinical observations from engineered NLCs that further underscore their translational relevance. From a translational standpoint, the review identifies NLC designs based on pharmaceutically accepted lipids, scalable preparation methods, and minimal surface complexity as the most feasible candidates for near-term clinical development, while more elaborate multifunctional or ligand-modified systems are discussed as promising but longer-term strategies. However, the progress outlined in this review highlights NLCs as a highly adaptable platform capable of unlocking curcumin's full pharmacological potential and accelerating its pathway toward therapeutic applicability.

Indexed as

CurcuminDrug CarriersLipidsNanostructuresAnimalsHumansCurcuminDrug CarriersLipidsbioavailability enhancementcurcumindrug deliverylipid-based nanoparticlesnanostructured lipid carriers

Identifiers

PMID41836730
PMCPMC12988807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.